论文信息 - Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group - 字舞流文

Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

F. Baron | H. Zwierzina | K. Indrák | G. Ossenkoppele | C. Denzlinger | M. Delforge | S. Suciu | S. Amadori | P. Muus | A. Thyss | D. Selleslag | T. de Witte | T. D. de Witte